Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
ProKidney Corp. is a clinical-stage biotechnology company developing autologous cell therapies to treat chronic kidney disease (CKD). Its lead product, rilparencel, uses patient-derived kidney cells to preserve kidney function and delay progression to end-stage renal disease. The company focuses on regenerative medicine, clinical trials, and manufacturing personalized therapies, targeting markets with high unmet needs in CKD management and aiming for regulatory approval and commercialization.
This description was generated via AI from an annual report. Updated about 1 year ago.